TP53 and neoplasm: Results showed that some genomic variants, such as TP53 56 and KMT2D 57, associated with worse clinical outcomes and tumor invasion were enriched in CTNND1-high group, while CTNND1-low groups had higher mutant frequency of some gene associated with immune infiltration and favorable outcomes, such as CACNA1C 58 and LMO7 59 (Supplementary Figure 8).